EQS-News

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Issuer: CureVac / Key word(s): Quarterly / Interim Statement CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 10.11.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

 

TÜBINGEN, Germany/ BOSTON, USA – November 10, 2022 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. ET.

 

Conference call and webcast details

 

Dial-in numbers to participate in the conference call:

U.S. Toll-Free:  [phone]

International: [phone]

Germany: 0800 182 0040

 

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/

 

Corresponding presentation slides will be posted shortly before the start of the webcast.

A replay will be made available at this website after the event.

 

 

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.